Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Imlifidase→

Imlifidase Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1947415-68-0
Molecular formula
C1575H2400N422O477S6
Molecular weight
35070 g/mol
Drug class
IgG-cleaving enzymeselective immunosuppressant
Mechanism of action
A cysteine protease derived from Streptococcus pyogenes that cleaves the heavy chains of human IgG, rapidly reducing donor-specific IgG antibodies and Fc-mediated effector activity.
Indications / reported uses
  • Desensitisation of highly sensitised adult kidney-transplant candidates with a positive crossmatch against an available deceased donor, under the authorised product indication.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix · https://www.medicines.org.uk/emc/product/13155/smpc

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Imlifidase Environmental Risk Assessment (ERA) (the Imlifidase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.